Impella

Type: Product
Name: Impella
First reported 23 hours ago - Updated 21 hours ago - 3 reports

ABIOMED's Impella RP Bags CE Mark - Analyst Blog

Leading provider of heart support technologies, ABIOMED, Inc. (NASDAQ: ABMD) secured the CE Mark approval to market its Impella RP (Right Peripheral) heart pump in the European Union. Shares of ABIOMED climbed 2.8% following the announcement last week, ... [Published Benzinga.com - 21 hours ago]
First reported Apr 16 2014 - Updated Apr 16 2014 - 1 reports

Abiomed buys rights to Opsens' optical sensor technology

Heart technologies company Abiomed (NasdaqGS:ABMD) disclosed on Tuesday the completion of the acquisition of an exclusive license for the use of certain optical sensor technology in the field of cardio-circulatory assist devices. Under an agreement, Abiomed ... [Published Individual.com - Apr 16 2014]
First reported Apr 15 2014 - Updated Apr 15 2014 - 2 reports

Opsens grants Abiomed US$6 million license for circulatory assist device

Canada NewsWireQUEBEC CITY, April 15, 2014QUEBEC CITYPursuant to this Agreement, Opsens will supply the sub-assembly of its miniature optical pressure sensor to be integrated in Abiomed's circulatory assist devices, including the Impella® line of heart ... [Published Digital Journal - Apr 15 2014]
First reported Apr 11 2014 - Updated Apr 11 2014 - 2 reports

Abiomed escapes shareholder lawsuit

by A federal judge dismisses a shareholder lawsuit filed over Abiomed's alleged off-label marketing of its Impella heart pump.Abiomed  (NSDQ: ABMD ) escaped a consolidated lawsuit filed over its alleged off-label marketing for the Impella 2.5 heart pump ... [Published MassDevice - Apr 11 2014]
First reported Apr 09 2014 - Updated Apr 09 2014 - 1 reports

Health Notes: Experts will field autism questions during an open house in Ponte Vedra Beach

Aylin Ozdemir, a physician with Pediatric Associates of Jacksonville, and autism expert Leslie Sinclair will be answering questions about autism during an open house from 4-7 p.m. April 15 at Ozdemir’s Ponte Vedra office, 1102 Florida A1A N., Unit 104, ... [Published Florida Times-Union - Apr 09 2014]
First reported Apr 08 2014 - Updated Apr 08 2014 - 3 reports

Abiomed wins CE Mark for Impella RP heart pump

by Abiomed says it won CE Mark approval in the European Union for its Impella RP right-side heart pump.Abiomed (NSDQ: ABMD ) said it won CE Mark approval in the European Union for its Impella RP heart pump, designed to assist the heart's right ventricle ... [Published MassDevice - Apr 08 2014]
First reported Mar 27 2014 - Updated Mar 27 2014 - 2 reports

Abiomed's Impella(R) Technology Showcased at ACC 2014 Scientific Sessions

Abiomed's Impella(R) Technology Showcased at ACC 2014 Scientific Sessions ... [Published Noodls - Mar 27 2014]
Entities: Impella
First reported Mar 27 2014 - Updated Mar 27 2014 - 1 reports

Medicare maintains reimbursement rate for Abiomed heart pump | Medtech Wall Street news for the week of Mar. 24, 2014

by Here's a look at some of the top Wall Street stories for medical device companies this week.March 21, 2014 by Brad PerrielloAbiomed said today that the Centers for Medicare & Medicaid Services plan to maintain the reimbursement rate for treatment with ... [Published MassDevice - Mar 27 2014]
First reported Mar 24 2014 - Updated Mar 24 2014 - 2 reports

ABIOMED's Impella Trial Achieves Enrollment Target - Analyst Blog

Impella RP is the latest in ABIOMED's line of Impella heart pumps. Impella 2.5, Impella 5.0, Impella CP and Impella LD have already secured the FDA pre-market approval.The Impella RP is currently the subject of an investigational device exemption (IDE) ... [Published Nasdaq - Mar 24 2014]
First reported Mar 21 2014 - Updated Mar 21 2014 - 2 reports

Abiomed Completes Enrollment in RECOVER RIGHT Trial of Impella RP

Abiomed has completed initial enrollment in its multicenter RECOVER RIGHT clinical trial of the Impella RP percutaneous heart pump.The study, conducted under an FDA investigational device exemption, is evaluating the device in 30 patients with right side ... [Published FDA News - Mar 21 2014]
First reported Mar 20 2014 - Updated Mar 21 2014 - 3 reports

Abiomed completes patient enrollment in RECOVER RIGHT Impella study

Abiomed has announced that the patient enrollment in the RECOVER RIGHT Impella study has been completed with the 30th patient enrolled in the study.The Investigational Device Exemption (IDE) study of Impella (right peripheral) has been designed to enroll ... [Published Medical Devices Business Review - Mar 21 2014]
First reported Mar 19 2014 - Updated Mar 19 2014 - 1 reports

Advances in Percutaneous Ventricular Assist Devices

P ercutaneous ventricular assist (pVAD) devices offer more hemodynamic support that the 40-year-old gold standard of intra-aortic balloon pumps (IABPs) , but their cost and complexity has limited their use to all but the sickest patients.  However, the ... [Published Diagnostic & Invasive Cardiology - Mar 19 2014]

Quotes

...platform to help our customers strive to achieve optimal patient outcomes," chairman, president & CEO Michael Minogue said in prepared remarks . "This exclusive licensing agreement between the Opsens and Impella technologies offers the ability to understand the role of myocardial unloading and wall tension, as well as the impact of recovery under a future 'smart' pumping algorithm."
...its partners the exploitation of its sensors in certain specific fields while directing its focus on the launch of its products for the FFR market. "The granting of this license enables Opsens to capitalize on its work with Abiomed over the years, while concentrating maximum efforts toward the FFR market, where the Company identifies an opportunity for exceptional growth" said Louis Laflamme
The FDA sent a warning letter to Abiomed in January 2010, according to the documents, "informing Abiomed that its promotional and marketing materials were making claims about the Impella 2.5 that were inappropriate and not supported for its intended use."
...proud to announce the commercial European availability of the new Impella RP device," said Michael R Minogue, Chairman, President and CEO, Abiomed. "This exciting news follows our recent announcement of the completion of patient enrollment in the US IDE RECOVER RIGHT trial, which further emphasizes the need for percutaneous support for right sided heart failure in hospitals around the world."

More Content

All (39) | News (34) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (4)
sort by: Date | Relevance
ABIOMED's Impella RP Bags CE Mark - Analyst Blog [Published Benzinga.com - 21 hours ago]
ABIOMED's Impella RP Bags CE Mark [Published Yahoo! Finance - 23 hours ago]
ABIOMED's Impella RP Bags CE Mark [Published Zacks.com - 23 hours ago]
Abiomed buys rights to Opsens' optical sensor t... [Published Individual.com - Apr 16 2014]
Abiomed reups license on Opsens fiber-optic pre... [Published MassDevice - Apr 15 2014]
Abiomed Acquires Exclusive License for Opsens' ... [Published DailyMe.Com - Apr 15 2014]
Opsens grants Abiomed US$6 million license for ... [Published Digital Journal - Apr 15 2014]
Opsens grants Abiomed US$6 million license for ... [Published TickerTech.com - Apr 15 2014]
Abiomed Acquires Exclusive License for Opsens' ... [Published Benzinga.com - Apr 15 2014]
Abiomed Acquires Exclusive License for Opsens' ... [Published Benzinga.com - Apr 15 2014]
Abiomed escapes shareholder lawsuit [Published MassDevice - Apr 11 2014]
Abiomed receives CE marking for right ventricul... [Published Individual.com - Apr 11 2014]
Health Notes: Experts will field autism questio... [Published Florida Times-Union - Apr 09 2014]
Abiomed wins CE Mark for Impella RP heart pump [Published MassDevice - Apr 08 2014]
Abiomed Gets CE Marking Approval In EU To Marke... [Published RTTNews.com - Apr 08 2014]
Abiomed Receives CE Mark for Impella RP [Published Benzinga.com - Apr 08 2014]
Baptist Medical Center Jacksonville has new hea... [Published Dotmed - Apr 07 2014]
Abiomed's Impella(R) Technology Showcased at AC... [Published Noodls - Mar 27 2014]
Medicare maintains reimbursement rate for Abiom... [Published MassDevice - Mar 27 2014]
Facility Investments, Earnings Release Schedule... [Published ADVFN India - Mar 27 2014]
Abiomed's Impella(R) Technology Showcased at AC... [Published Benzinga.com - Mar 27 2014]
ABIOMED's Impella Trial Achieves Enrollment Tar... [Published Nasdaq - Mar 24 2014]
ABIOMED's Impella Trial Achieves Enrollment Target [Published Yahoo! Finance - Mar 24 2014]
Gilead offers Egypt new hepatitis C drug at 99 ... [Published BioMedReports - Mar 22 2014]
Abiomed Completes Enrollment in RECOVER RIGHT T... [Published FDA News - Mar 21 2014]
Abiomed jumps on Medicare reimbursement news [Published MassDevice - Mar 21 2014]
Impella Maintains Existing Diagnosis Related Gr... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Abiomed completes patient enrollment in RECOVER... [Published Medical Devices Business Review - Mar 21 2014]
QIAGEN Launches QuantiFERON-TB Gold In-Tube in ... [Published BioMedReports - Mar 21 2014]
Abiomed hits enrollment goal in Recover Right t... [Published MassDevice - Mar 20 2014]
1 2
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Forbion Capital-backed uniQure completes IPO [Published PE Hub Blog - Feb 13 2014]
Forbion Capital Partners -backed uniQure , which develops gene therapy products, has completed an initial public offering at a price of $17 per share on the NASDAQ . Jefferies and Leerink Partners acted as joint book-running managers and Piper ...
1

Press Releases

sort by: Date | Relevance
Impella Maintains Existing Diagnosis Related Gr... [Published GlobeNewswire: Acquisitions News - Mar 21 2014]
Abiomed Completes Patient Enrollment in RECOVER... [Published GlobeNewswire: Acquisitions News - Mar 20 2014]
Abiomed Announces Second Quarter Fiscal 2014 Re... [Published GlobeNewswire: Advertising News - Nov 06 2013]
Abiomed's Impella(R) Technology Showcased at TC... [Published GlobeNewswire: Acquisitions News - Oct 23 2013]
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.